PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension

Inclusion Criteria: * Patients who are 20-80 years of age * Patients with essential hypertension (90 mmHg ≤ DBP ≤ 110 mmHg and/or 140 mmHg ≤ SBP ≤ 180 mmHg) whose BP is not adequately controlled with amlodipine (or another CCB) alone or with valsartan (or another ARB) alone, or with any antihypertensive monotherapy. * Agree to and are able to follow the study procedures * Understand the nature of the study, and have signed informed consent forms Exclusion Criteria: * Patients with any of the following conditions: 1. Malignant (or history of malignant) hypertension 2. Secondary hypertension 3. Severe hypertension (mean sitting DBP ≥ 110 mmHg and/or mean sitting SBP ≥ 180 mmHg) 4. A history of hypertensive encephalopathy or cerebrovascular accident 5. Cerebrovascular accident, myocardial infraction within 3 months, or any type of revascularization 6. New York Heart Association class III -IV congestive heart failure 7. Second- or third-degree heart block 8. Angina pectoris 9. Significant arrhythmia or valvular heart disease 10. Significant pancreatic, hepatic, or renal disease 11. Diabetes requiring insulin treatment or poorly controlled type 2 diabetes * Patients with known contraindication or a history of allergy to CCBs or ARBs. * Female patients who are pregnant or lactating. * Male or female patients of child-bearing potential who do not agree to use an effective method of contraception during the study * Patients is currently participating in any other clinical trial within 30 days